143 related articles for article (PubMed ID: 36106543)
1. Effectiveness of apremilast against Behçet's disease-associated mucocutaneous and joint involvement confirmed through switching from adalimumab.
Azuma N; Matsui K
Clin Exp Rheumatol; 2022 Sep; 40(8):1605-1606. PubMed ID: 36106543
[No Abstract] [Full Text] [Related]
2. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome.
Saini A; Ferguson C; Salkey K
J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267
[TBL] [Abstract][Full Text] [Related]
3. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
4. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
5. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
6. [An update on Behçet's syndrome].
Xenitidis T; Henes JC
Laryngorhinootologie; 2024 May; 103(5):352-357. PubMed ID: 38330997
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
8. Healing of Mucocutaneous Lesions With Apremilast in Behçet Disease.
Moya P; Castellví I; Magallares B; Millan M; Wilson N; Corominas H
J Clin Rheumatol; 2020 Aug; 26(5):e132. PubMed ID: 30896462
[No Abstract] [Full Text] [Related]
9. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease.
Lopalco G; Venerito V; Leccese P; Emmi G; Cantarini L; Lascaro N; Di Scala G; Fabiani C; Rigante D; Iannone F
Ann Rheum Dis; 2019 Dec; 78(12):1736-1737. PubMed ID: 31401548
[No Abstract] [Full Text] [Related]
10. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
12. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
13. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
15. Marked improvement in gastric involvement in Behçet's disease with adalimumab treatment.
Sonoda A; Ogawa R; Mizukami K; Fukuda K; Shuto M; Okamoto K; Matsunari O; Okimoto T; Murakami K
Turk J Gastroenterol; 2017 Sep; 28(5):405-407. PubMed ID: 28797990
[TBL] [Abstract][Full Text] [Related]
16. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
17. Off-label studies on apremilast in dermatology: a review.
Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
[No Abstract] [Full Text] [Related]
18. Behcet disease: A new therapeutic agent. [corrected].
Robinson AN; Scully C
Br Dent J; 2015 May; 218(10):557. PubMed ID: 25998333
[No Abstract] [Full Text] [Related]
19. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide in Behçet's disease.
Shek LP; Lim DL
Biomed Pharmacother; 2002 Feb; 56(1):31-5. PubMed ID: 11908493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]